Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice
- PMID: 16914135
- DOI: 10.1016/j.ejphar.2006.07.009
Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice
Abstract
Anti-pruritic effects of the antihistamine bepotastine besilate were studied in mice. Bepotastine besilate (10 mg/kg) inhibited scratching induced by an intradermal injection of histamine (100 nmol/site), but not serotonin (100 nmol/site). Bepotastine besilate (1-10 mg/kg, oral) dose-dependently suppressed scratching induced by substance P (100 nmol/site) and leukotriene B(4) (0.03 nmol/site). An intradermal injection of substance P (100 nmol/site) increased the cutaneous concentration of leukotriene B(4), which was not affected by bepotastine besilate (10 mg/kg, oral). Leukotriene B(4) increased Ca(2+) concentration in cultured neutrophils, which was suppressed by bepotastine besilate (1-100 microM). Leukotriene B(4) increased Ca(2+) concentration in cultured dorsal root ganglion neurons, which was also suppressed by bepotastine besilate (100 microM). The results suggest that the inhibition of the actions of leukotriene B(4) as well as histamine is involved in the anti-pruritic effect of bepotastine besilate.
Similar articles
-
Oral administration of bepotastine besilate suppressed scratching behavior of atopic dermatitis model NC/Nga mice.Int Arch Allergy Immunol. 2008;145(4):277-82. doi: 10.1159/000110886. Epub 2007 Nov 13. Int Arch Allergy Immunol. 2008. PMID: 18004068
-
Bepotastine besilate, a highly selective histamine H(1) receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.Exp Eye Res. 2010 Jul;91(1):85-91. doi: 10.1016/j.exer.2010.04.006. Epub 2010 Apr 20. Exp Eye Res. 2010. PMID: 20412793
-
Inhibitory effects of azelastine on substance P-induced itch-associated response in mice.Eur J Pharmacol. 2002 Feb 2;436(3):235-9. doi: 10.1016/s0014-2999(01)01617-x. Eur J Pharmacol. 2002. PMID: 11858803
-
Bepotastine besilate for the treatment of pruritus.Expert Opin Pharmacother. 2013 Dec;14(18):2553-69. doi: 10.1517/14656566.2013.849242. Epub 2013 Nov 5. Expert Opin Pharmacother. 2013. PMID: 24191914 Review.
-
Non-clinical pharmacology, pharmacokinetics, and safety findings for the antihistamine bepotastine besilate.Curr Med Res Opin. 2010 Oct;26(10):2329-38. doi: 10.1185/03007995.2010.486753. Curr Med Res Opin. 2010. PMID: 20735291 Review.
Cited by
-
Inhibition of RAN attenuates influenza a virus replication and nucleoprotein nuclear export.Emerg Microbes Infect. 2024 Dec;13(1):2387910. doi: 10.1080/22221751.2024.2387910. Epub 2024 Aug 12. Emerg Microbes Infect. 2024. PMID: 39087696 Free PMC article.
-
Efficacy and Toxicity Evaluation of Bepotastine Besilate 1.5% Preservative-Free Eye Drops Vs Olopatadine Hydrochloride 0.2% Bak-Preserved Eye Drops in Patients with Allergic Conjunctivitis.Clin Ophthalmol. 2023 Nov 16;17:3477-3489. doi: 10.2147/OPTH.S431889. eCollection 2023. Clin Ophthalmol. 2023. PMID: 38026598 Free PMC article. Clinical Trial.
-
Treatment of allergic conjunctivitis with bepotastine besilate ophthalmic solution 1.5%.Clin Ophthalmol. 2014 Aug 13;8:1495-505. doi: 10.2147/OPTH.S66637. eCollection 2014. Clin Ophthalmol. 2014. PMID: 25152611 Free PMC article.
-
Relationship between the Degrees of Itch and Serum Lipocalin-2 Levels in Patients with Psoriasis.J Immunol Res. 2019 Jan 21;2019:8171373. doi: 10.1155/2019/8171373. eCollection 2019. J Immunol Res. 2019. PMID: 30805373 Free PMC article.
-
Oral bepotastine: in allergic disorders.Drugs. 2010 Aug 20;70(12):1579-91. doi: 10.2165/11205880-000000000-00000. Drugs. 2010. PMID: 20687621 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous